3 ms·
Depends on if that mechanism of action works for the particular exact set of mutations that the given tumor has (every cancer is essentially unique). Part of th
by vikramkr 3y ago
Depends on if that mechanism of action works for the particular exact set of mutations that the given tumor has (every cancer is essentially unique). Part of the success of the work in that paper is identifying specific markers that indicate that the drug is going to work in that tumor
- adamredwoods 3y agoBoth dostarlimab and pembro are PD-1 blockers, yet they are labeled for two different cancers. If all tumors have different characteristics, why are these not labeled for all cancers, in general, that display these expressions? Is this part of the game that the FDA plays?
- vikramkr 3y agoThey are: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature https://www.fda.gov/news-events/press-announcements/fda-appr... https://en.wikipedia.org/wiki/Tissue-agnostic_cancer_drug https://en.wikipedia.org/wiki/Tissue-agnostic_cancer_drug If by "game" you mean rigorous regulatory process to ensure safety and efficacy, then yeah. Different monoclonal antibodies even with the same target can behave differently. You'd have to specifically design a trial and seek approval for an indication like the one you described. Which people have done and are doing. It's an exciting field of research!